• KOL
    • Alzheimer Disease
    • John Q Trojanowski
    • John Q Trojanowski: Influence Statistics

      John Q Trojanowski

      John Q Trojanowski

      Show email address

      Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA | Center for Neurodegenerative Disease Research, Department ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      John Q Trojanowski:Expert Impact

      Concepts for whichJohn Q Trojanowskihas direct influence:Alzheimer disease,Lewy bodies,Alzheimers disease,Tau pathology,Neurodegenerative diseases,Amyotrophic lateral sclerosis,Frontotemporal dementia,Parkinson disease.

      John Q Trojanowski:KOL impact

      Concepts related to the work of other authors for whichfor which John Q Trojanowski has influence:Alzheimer disease,Lewy bodies,Amyotrophic lateral sclerosis,Cognitive impairment,Frontotemporal dementia,Oxidative stress,Traumatic brain injury.

      KOL Resume for John Q Trojanowski

      Year
      2022

      Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

      Departments of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

      Department of Pathology and Laboratory Medicine, University of Pennsylvania

      2021

      Department of Geriatric Medicine and Gerontology, University of Pennsylvania Health System, Philadelphia, PA USA

      Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania, 19104, United States

      Sign-in to see all concepts, it's free!
      Sample of concepts for which John Q Trojanowski is among the top experts in the world.
      Concept World rank
      patient lewy bodies #1
      neuropsychological measures measures #1
      c9p ftld #1
      cases mabs #1
      atpzs #1
      nf antigens neurons #1
      wgahrp wga #1
      tauopathies1 #1
      hippocampus nfts #1
      neuronal morphologic features #1
      endogenous αsyn aggregation #1
      putgs #1
      stereotaxic targeting #1
      csf fdg uptake #1
      pathology tau #1
      pars nervosa development #1
      tau immunophenotypes #1
      dementia atrophy rates #1
      low sappβ #1
      inclusions neurons #1
      tauopathies glial pathology #1
      confirms cr1 #1
      vitro fibril forms #1
      csf biomarkers risk #1
      mriscore #1
      c9p cases #1
      disease tdp43 #1
      scc baseline #1
      rat brain abeta #1
      prototype therapeutics #1
      empiric refinement #1
      hb vhl disease #1
      msut2 polya #1
      tbi mechanisms #1
      pathologically confirmed ftld #1
      ndaps #1
      deliberate haste #1
      axonal transport onset #1
      “fatal attractions #1
      proteins aβ42 reduction #1
      mnd nf inclusions #1
      psen1 load #1
      ftldu mabs #1
      neuronal inclusions nifid #1
      tubers molecular phenotype #1
      nfh tumors #1
      syn tau #1
      hippocampus upr activation #1
      10 mechanisms #1
      selective downgaze paralysis #1
      Sign-in to see all concepts, it's free!

      Prominent publications by John Q Trojanowski

      KOL-Index: 18671

      The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The study aimed to enroll 400 subjects with early mild cognitive impairment (MCI), 200 subjects with early AD, and 200 normal control subjects; $67 million funding was provided by both the public and private sectors, including the National Institute ...

      Known for Disease Neuroimaging | Csf Biomarkers | Early Detection | Clinical Tests | Establishment Adni
      KOL-Index: 17968

      OBJECTIVE: To assess the correlations of both MRI and CSF biomarkers with clinical diagnosis and with cognitive performance in cognitively normal (CN) subjects and patients with amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD).

      METHODS: This is a cross-sectional study with data from the Alzheimer's Disease Neuroimaging Initiative, which consists of CN subjects, subjects with aMCI, and subjects with AD with both CSF and MRI. Baseline CSF (t-tau, Abeta(1-42), and ...

      Known for Csf Biomarkers | Amci Subjects | Cognitive Scores | Proteins Aged | Mri Scans
      KOL-Index: 17379

      OBJECTIVES: To determine whether genotypes at CLU, PICALM, and CR1 confer risk for Alzheimer disease (AD) and whether risk for AD associated with these genes is influenced by apolipoprotein E (APOE) genotypes.

      DESIGN: Association study of AD and CLU, PICALM, CR1, and APOE genotypes.

      SETTING: Academic research institutions in the United States, Canada, and Israel.

      PARTICIPANTS: Seven thousand seventy cases with AD, 3055 with autopsies, and 8169 elderly cognitively normal controls, 1092 ...

      Known for Apoe Genotypes | Alzheimer Disease Risk | Clu Picalm | Single Nucleotide Receptors | European Ancestry
      KOL-Index: 16881

      IMPORTANCE: Cognitive impairment is a common and disabling problem in Parkinson disease (PD) that is not well understood and is difficult to treat. Identification of genetic variants that influence the rate of cognitive decline or pattern of early cognitive deficits in PD might provide a clearer understanding of the etiopathogenesis of this important nonmotor feature.

      OBJECTIVE: To determine whether common variation in the APOE, MAPT, and SNCA genes is associated with cognitive ...

      Known for Cognitive Performance | Parkinson Disease | Apoe Ε4 Allele | Patients Dementia | Trail Making Test
      KOL-Index: 16514

      A new panel of greater than 300 monoclonal antibodies (mAbs) was prepared to the high, middle, and low Mr rat neurofilament (NF) subunits (NF-H, NF-M and NF-L, respectively). NF proteins were purified both from native, i.e., phosphorylated rat NFs and from enzymatically dephosphorylated rat NFs. The resulting mAbs were used to biochemically and immunochemically distinguish and characterize distinct and differentially phosphorylated isoforms of NF subunits. By immunoblot, all mAbs ...

      Known for Monoclonal Antibodies | Nfh Nfm | Adult Rats | Neurofilament Subunits | Nf Proteins
      KOL-Index: 16367

      Importance: Neuronal and axonal destruction are hallmarks of neurodegenerative diseases, but it is difficult to estimate the extent and progress of the damage in the disease process.

      Objective: To investigate cerebrospinal fluid (CSF) levels of neurofilament light (NFL) protein, a marker of neuroaxonal degeneration, in control participants and patients with dementia, motor neuron disease, and parkinsonian disorders (determined by clinical criteria and autopsy), and determine its ...

      Known for Neurofilament Light | Nfl Levels | Alzheimer Disease | Frontotemporal Dementia | Motor Neuron
      KOL-Index: 16083

      BackgroundTREM2 is a transmembrane receptor that is predominantly expressed by microglia in the central nervous system. Rare variants in the TREM2 gene increase the risk for late-onset Alzheimer’s disease (AD). Soluble TREM2 (sTREM2) resulting from shedding of the TREM2 ectodomain can be detected in the cerebrospinal fluid (CSF) and is a surrogate measure of TREM2-mediated microglia function. CSF sTREM2 has been previously reported to increase at different clinical stages of AD, however, ...

      Known for Csf Strem2 | Tau Pathology | Clinical Stages | Alzheimer Disease | Soluble Trem2
      KOL-Index: 15937

      OBJECTIVE: To compare the diagnostic performance of PET with the amyloid ligand Pittsburgh compound B (PiB-PET) to fluorodeoxyglucose (FDG-PET) in discriminating between Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD).

      METHODS: Patients meeting clinical criteria for AD (n = 62) and FTLD (n = 45) underwent PiB and FDG-PET. PiB scans were classified as positive or negative by 2 visual raters blinded to clinical diagnosis, and using a quantitative threshold derived from ...

      Known for Pib Fdg | Differential Diagnosis | Higher Sensitivity | Clinical Criteria | Diagnostic Performance
      KOL-Index: 15806

      Biomarkers of brain Aβ amyloid deposition can be measured either by cerebrospinal fluid Aβ42 or Pittsburgh compound B positron emission tomography imaging. Our objective was to evaluate the ability of Aβ load and neurodegenerative atrophy on magnetic resonance imaging to predict shorter time-to-progression from mild cognitive impairment to Alzheimer's dementia and to characterize the effect of these biomarkers on the risk of progression as they become increasingly abnormal. A total of ...

      Known for Mild Cognitive Impairment | Magnetic Resonance | Aβ Load | Hippocampal Atrophy | Time Progression
      KOL-Index: 15791

      This study evaluates the individual, as well as relative and joint value of indices obtained from magnetic resonance imaging (MRI) patterns of brain atrophy (quantified by the SPARE-AD index), cerebrospinal fluid (CSF) biomarkers, APOE genotype, and cognitive performance (ADAS-Cog) in progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) within a variable follow-up period up to 6 years, using data from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI-1). ...

      Known for Brain Atrophy | Csf Biomarkers | Apoe Genotype | Spatial Patterns | Clinical Progression
      KOL-Index: 15777

      The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The study aimed to enroll 400 subjects with early mild cognitive impairment (MCI), 200 subjects with early AD, and 200 normal control subjects; $67 million funding was provided by both the public and private sectors, including the National Institute ...

      Known for Disease Neuroimaging | Csf Biomarkers | Early Detection | Clinical Tests | Papers Published
      KOL-Index: 15626

      Lewy bodies commonly occur in Alzheimer's disease, and Alzheimer's disease pathology is frequent in Lewy body diseases, but the burden of co-pathologies across neurodegenerative diseases is unknown. We assessed the extent of tau, amyloid-β, α-synuclein and TDP-43 proteinopathies in 766 autopsied individuals representing a broad spectrum of clinical neurodegenerative disease. We interrogated pathological Alzheimer's disease (n = 247); other tauopathies (n = 95) including Pick's disease, ...

      Known for Neurodegenerative Disease | Lewy Body | Amyotrophic Lateral Sclerosis | Pathology Alzheimer | Synuclein Tdp43
      KOL-Index: 15612

      In 6 adolescent rhesus monkeys, unilateral injections of horseradish peroxidase (HRP) were made into 6 regions on the convexity of the prefrontal granular cortex.The afferents to each zone were considered with respect to whether they were local afferents (from adjacent frontal areas) or distal afferents (from outside frontal lobe). The strongest input onto prefrontal granular cortex comes from the temporal lobe and especially areas in and around the superior temporal gyrus. Area 10 in ...

      Known for Prefrontal Granular Cortex | Superior Temporal Sulcus | Rhesus Monkey | Labeled Neurons | Injections Area
      KOL-Index: 15607

      BACKGROUND: The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational, longitudinal cohort study of participants with Parkinson's disease, healthy controls, and carriers of the most common Parkinson's disease-related genetic mutations, which aims to define biomarkers of Parkinson's disease diagnosis and progression. All participants are assessed annually with a battery of motor and non-motor scales, 123-I Ioflupane dopamine transporter (DAT) imaging, and ...

      Known for Gba Lrrk2 | Parkinsons Disease | Manifesting Carriers | Dopamine Transporter | Progression Markers
      KOL-Index: 15580

      BACKGROUND: Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We aimed to identify genetic and pathological markers that have the strongest association with these features of clinical heterogeneity in synucleinopathies.

      METHODS: In this retrospective study, we examined symptom onset, and genetic and neuropathological data from a cohort of patients with Lewy body disorders with autopsy-confirmed α ...

      Known for Dementia Onset | Alzheimer Disease | National Institute | Motor Symptoms | Retrospective Analysis

      Key People For Alzheimer Disease

      Top KOLs in the world
      #1
      John Carl Morris
      alzheimer disease cognitive impairment lewy bodies
      #2
      Bradley T Hyman
      alzheimer disease lewy bodies neurofibrillary tangles
      #3
      Ronald Carl Petersen
      mild cognitive impairment alzheimer disease lewy bodies
      #4
      John Anthony Hardy
      alzheimer disease frontotemporal dementia lewy bodies
      #5
      Dennis J Selkoe
      alzheimer disease amyloid beta precursor protein
      #6
      John Q Trojanowski
      alzheimer disease lewy bodies tau pathology

      Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA | Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the U

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.